Tumor Necrosis Factor (TNF) Inhibitors Tumor necrosis factor (TNF) promotes the inflammatory response, which in turn causes many of the clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, hidradenitis suppurativa and refractory asthma. These disorders are sometimes treated by using a TNF inhibitor, also known as TNF blocker.
Tumor Necrosis Factor (TNF) Signaling Pathway The tumor necrosis factor (TNF) superfamily of cytokines activate signaling pathways for cell survival, death, and differentiation. Members of the tumor necrosis factor superfamily act through ligand-mediated trimerization, causing recruitment of several intracellular adaptors to activate multiple signal transduction pathways. Recruitment of death domain (DD) containing adaptors such as Fas associated death domain (FADD) and TNFR associated DD (TRADD) can lead to the activation of a signal transduction pathway that induces apoptosis. While recruitment of TRAF family proteins can lead to the activation of transcription factors such as, NF-kappaB and JNK thereby promoting cell survival and differentiation as well as immune and inflammatory responses.
Anti TNF Therapy / Anti TNF Drugs Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti TNF drugs / agents has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis.
TNF relevant products:
Use the filter on the right or the search box below to find your product.
Sensitivity: The minimum detectable dose of Ferret CD4 / Leu-3 was determined to be approximately 31.25 pg/ml. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard. Detection: 31.25 pg/ml
Sensitivity: The minimum detectable dose of human CD48 (BCM-1 / SLAMF2) was determined to be approximately 15.6 pg/ml. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard. Detection: 15.6 pg/ml
Sensitivity: The minimum detectable dose of Human CD30 / TNFRSF8 was determined to be approximately 24 pg/ml. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard. Detection: 24 pg/ml
Sensitivity: The minimum detectable dose of Human G-CSF R / CD114 / CSF3R was determined to be approximately 50 pg/ml. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard. Detection: 50 pg/ml
Sensitivity: The minimum detectable dose of H1N1 (A/Puerto Rico/8/1934) HA was determined to be approximately 46.88 pg/ml. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard. Detection: 46.88 pg/ml